Sundar PichaiSundar Pichai earned $164M in 2023
F

Alex C. Sapir

CEO of Fulcrum Therapeutics, Inc.

Education

B.A. in Economics from Franklin and Marshall College, M.B.A. from Harvard Business School.

Field of Expertise

Business & Management

Born

January 1, 1967 - 58 years ago

Economy Sector

Healthcare

Current Tenure

1 year 7 months (Jul 2023 - Present)

Previous Experience

CEO of ReViral Ltd.; CEO of Dova Pharmaceuticals Inc.; Executive Vice President for Marketing and Sales at United Therapeutics Corporation.

Alex C. Sapir is the current CEO and President of Fulcrum Therapeutics, Inc., having stepped into the role on July 1, 2023. Previously, he led ReViral Ltd., a biopharmaceutical firm that specialized in antiviral treatments until its acquisition by Pfizer...

Year

2023

Total Compensation

$591.84K

Salary

$369.42K

Board Justification

The compensation philosophy aligns with company performance, peer benchmarking, and retention strategies, focusing on motivating executives to achieve annual goals based on strategic, financial, and operational performance objectives.

Bonus

$150.00K

Board Justification

The bonus is based on performance metrics and was awarded at 85% of the target for 2023, reflecting Mr. Sapir's pro-rated participation since his employment began in July 2023.

Other

$72.42K

Board Justification

Other compensation includes a housing and travel allowance and a tax gross-up related to the taxable housing and travel allowance.

Restricted Stock

$0.00(0 common stock)

Board Justification

No stock was reported as vested in 2023.

Performance Metrics

The performance metrics for determining the compensation included development goals related to advancing product candidates and operational management.